Helmholtz Zentrum München/IES

Stem Cell Research: (Re)-acquiring The Potential To Become Everything

ArticlePress release
Current Medical News
Contributed byKrish Tangella MD, MBAJan 10, 2018

A new study in Nature Genetics identifies a specific population of pluripotent embryonic stem cells that can reprogram to totipotent-like cells in culture. Moreover, the scientists of Helmholtz Zentrum München and Ludwig-Maximilians-Universität München (LMU) have identified bottlenecks and drivers of this reprogramming.

Cellular plasticity is the ability of a cell to make different cell types. At the early stages of life, the fertilized single-cell coming from the mother's egg and the father's sperm is highly plastic -- it will give rise to all of the cell types of the body. Cellular plasticity is therefore essential for multicellular organisms like humans to exist.

The single fertilized cell first divides into two cells (referred to as the 2-cell stage of development). The single cell and the two cells resulting from it, have the highest level of cellular plasticity: They are totipotent, which means they can make a full organism, including the extra-embryonic placental tissue. In contrast, embryonic stem cells are pluripotent which means they can make all the cells of the organism, but typically not the extra-embryonic tissue.

In a culture of embryonic stem (ES) cells, a small population (around 1%) spontaneously turns into cells that are similar to the totipotent cells of the 2-cell stage embryo. These cells are called 2-cell-like cells (2CLCs). In this study, Prof. Dr. Maria Elena Torres-Padilla's team set out to determine the specific molecular nature of these cells and find out how they come to be. Torres-Padilla is director of the Institute of Epigenetics and Stem Cells (IES) at Helmholtz Zentrum München and professor of Stem Cell Biology at the LMU. The aim of the team was to gain insights in to the molecular features of totipotency and to work out how changes in cellular plasticity may occur. Their ultimate goal is to understand how these totipotent-like cells 'behave' so that they can manipulate them, and generate them in vitro.

The team began by comparing the genes expressed in ES cells to those expressed in 2CLCs. To do this they used ES cells which express a green fluorescent protein when cells start expressing the MERVL gene. "MERVL is a retrotransposon expressed in 2-cell-like cells" explains Diego Rodriguez-Terrones, a PhD student in the Torres-Padilla lab and co-first author of the paper. "Using this cell line allows us to separate 2-cell-like cells from the ES cells in the culture by collecting the green cells which have entered the 2-cell like state. We then compare the genes expressed in both cell types" he adds. This single cell transcriptome analysis followed by computational analyses enabled the team to identify the gene expression profiles of cells in the process of changing from ES cells to 2CLCs.

They found that during the transition period, cells expressed increasing amounts of a gene encoding the transcription factor Zscan4. They developed their reporter line to also be able to express a red fluorescent protein when Zscan4 is expressed. Live cell imaging confirmed that the majority of cells became red (Zscan4 positive) before becoming green (MERVL positive 2-cell-like cells). "This observation, combined with the transcriptomic data, told us that cells transition through an intermediate state before becoming 2-cell-like cells" said Maria Elena Torres-Padilla. "Based on these seemingly ordered changes in gene expression, we wanted to find out what might be driving the emergence of the 2-cell-like state. This information would be crucial for furthering our knowledge concerning key regulators of cellular plasticity."

With the goal of identifying chromatin regulators that can promote cellular reprogramming, the team performed an siRNA screen, in which the expression of over 1000 genes was impaired to see how the appearance of 2CLCs was affected. "The results of this screen were extraordinary, because we identified many novel proteins that regulate the emergence of 2CLCs" said Dr. Xavier Gaume, co-first author of the paper and postdoc in the Torres-Padilla lab. Of particular interest was the observation that reducing levels of a specific chromatin factor (Ep400/Tip60), results in more 2CLCs. As Ep400/Tip60 is involved in chromatin compaction, this observation identifies an interesting link between chromatin 'openness' with increased potency.

Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!